Previous 10 | Next 10 |
2023-05-08 10:57:48 ET Summary Viatris has struggled to gain ground over the last year. This has happened despite management stressing the free cash flow generation ability of the business. Q1-2023 results showed just how much work management needs to do to make this a comebac...
2023-05-08 10:31:29 ET Summary Viatris Inc. reports 5th consecutive quarterly sales decline. Q1 saw the company's 2nd highest free cash flow as a stand-alone. The Viatris dividend appears safe, but increases may need to wait with sales concerns. I recommend waiting at leas...
2023-05-08 07:47:09 ET Viatris press release ( NASDAQ: VTRS ): Q1 GAAP EPS of $0.19 Revenue of $3.72B (-11.2% Y/Y) misses by $90M . U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP Net Cash Provided by Operating Act...
2023-05-08 07:41:02 ET Indicating a ~11% YoY decline in total revenue, Viatris ( NASDAQ: VTRS ) continued to report declining sales for the fifth consecutive quarter with its Q1 2023 financials on Monday while signaling a potential recovery in the years ahead. VTRS, established ...
2023-05-08 07:00:00 ET Summary Fuji Pharma Co., Ltd. is mainly a generics pharma company focused on the less volatile Japanese generics market, whose market structure is associated with less regulatory risks, competition, and generics profitability risks. Its generics focus is a p...
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] PR Newswire Reports Total Revenues of $3.73 billion ; U.S. GAAP Net Earnings of $225 million ; Adjusted EBITDA of $1.34 billion ; U.S. ...
2023-05-05 14:00:36 ET Earnings season continues next week, although the pace of releases begins to slow. Entertainment companies provide key highlights during the period, with reports due out from Disney ( DIS ) and Fox ( FOX ). Outside of media, both the pharmaceutical and EV ...
2023-05-05 11:24:04 ET Viatris ( NASDAQ: VTRS ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is $0.70 (+112.1% Y/Y) and the consensus Revenue Estimate is $3.81B (-9.1% Y/Y). Over the last 1 year, VTRS h...
2023-05-04 14:28:38 ET Summary Organon reported obviously disappointing results today - OGN stock plunged more than 10% in response. In this update, I share my view on Organon's quarterly results and point out possible warning signs and reasons for the sell-off. I give an upda...
2023-04-27 09:45:00 ET If you have $20,000 or more in savings that you can afford to invest in stocks, you may want to consider putting that in some high-yielding investments that can provide you with some great recurring income. Viatris (NASDAQ: VTRS) and AT&T (NYSE: ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...